The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.
Specialty Pharmacy News
Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use.
Diplomat announced a new partnership with Novation through their Hospital Specialty Rx Program on Thursday.
Mylan on Thursday announced that its subsidiary, Mylan Labs, was granted tentative approval from the Food and Drug Administration for two dosages of abacavir/lamivudine tablets for oral suspension.
Diplomat Pharmacy announced Wednesday that it has been selected to Pfizer's limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.
Ranbaxy Laboratories on Monday announced the launch of Infimab (BOW015), the first Remicade (Infliximab) biosimilar in India. The product was launched at the Indian Rheumatology Association Conference in Chandigarh.
Just 30% of Americans with HIV had the virus under control in 2011, and approximately two-thirds of those whose virus was out of control had been diagnosed but were no longer in care.
Omnicare and McKesson on Monday announced the signing of an expanded agreement to include the sourcing and distribution of branded, specialty and generic pharmaceuticals.
Decision Resources Group found that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim could reach $1.8 billion in the United States by 2023.
More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.